Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.77 |
| ▸ | PRKACA | P17612 | 2/20 | 0.65 |
| ▸ | PRKACG | P22612 | 2/20 | 0.65 |
| ▸ | PRKACB | P22694 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6857883 | 0.92 | AKT1 (0.77) | AKT1PRKACAPRKACGPRKACB | |
| SCHEMBL6853533 | 0.90 | AKT1 (0.63) | AKT1PRKACAPRKACGPRKACB | |
| SCHEMBL6849737 | 0.90 | AKT1 (0.63) | AKT1PRKACAPRKACGPRKACB | |
| SCHEMBL6853384 | 0.90 | AKT1 (0.77) | AKT1PRKACAPRKACGPRKACB | |
| SCHEMBL6849762 | 0.90 | AKT1 (0.67) | AKT1PRKACAPRKACGPRKACB | |
| SCHEMBL6855551 | 0.89 | AKT1 (0.68) | AKT1PRKACAPRKACGPRKACB | |
| SCHEMBL6857971 | 0.89 | AKT1 (0.77) | AKT1PRKACAPRKACGPRKACB | |
| SCHEMBL6855388 | 0.88 | AKT1 (0.78) | AKT1PRKACAPRKACGPRKACB | |
| SCHEMBL6854927 | 0.87 | AKT1 (0.68) | AKT1 | |
| SCHEMBL6853549 | 0.87 | AKT1 (0.79) | AKT1PRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | claimed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | claimed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | claimed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | AKT1 119/4885PRKACA 27/4885PRKACG 37/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | AKT1 119/4885PRKACA 27/4885PRKACG 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.